Endo Acquires BioSpecifics

Endo International has completed its acquisition of BioSpecifics.

Endo International plc logo
Endo International plc logo

Endo International has completed its acquisition of BioSpecifics Technologies Corp.

Under the terms of a previous strategic relationship, BioSpecifics received royalties from Endo related to Endo's collagenase-based therapies, including XIAFLEX, marketed by Endo Pharmaceuticals, for the treatment of Dupuytren's contracture and Peyronie's disease, and QWO, the first FDA-approved injectable treatment for cellulite, which is expected to be launched by Endo Aesthetics in 2021.

Endo acquired BioSpecifics for $88.50 per share in an all-cash transaction, for an estimated value of $540 million (net of approximately $120 million in cash acquired).

As a result of the acquisition, BioSpecifics ceased to be a publicly traded company and became a wholly-owned subsidiary of Endo.



More in News